List of Excipients in Branded Drug CELECOXIB 200 MG

« Back to Dashboard

Generic Drugs Containing CELECOXIB 200 MG

Company	Ingredient	NDC	Excipient
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	CROSCARMELLOSE SODIUM
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	FERRIC OXIDE RED
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	GELATIN
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	LACTOSE MONOHYDRATE
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	MAGNESIUM STEARATE
Aidarex Pharmaceuticals LLC	celecoxib	53217-206	POVIDONE K30

What are the Most Frequently-Used Excipients in CELECOXIB 200 MG?

# Of NDCs	Excipient
4	CROSCARMELLOSE SODIUM
4	FERRIC OXIDE RED
4	GELATIN
4	LACTOSE MONOHYDRATE
4	MAGNESIUM STEARATE
4	POVIDONE K30

Celecoxib 200 mg Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

Celecoxib 200 mg is a mature, genericized small-molecule product with limited protection from active-ingredient patents. Commercial differentiation depends on dissolution performance, capsule and tablet platform selection, patient tolerability, manufacturing cost, supply reliability, and regulatory execution. The strongest opportunity is not a conventional copy of the reference capsule. It is a bioequivalent product with improved manufacturability, reduced excipient complexity, differentiated dosage form, or enhanced performance in patients with swallowing, gastrointestinal, or adherence problems.

What is the regulatory and commercial status of celecoxib 200 mg?

Celecoxib is a selective cyclooxygenase-2 inhibitor approved for osteoarthritis, rheumatoid arthritis, acute pain, and primary dysmenorrhea. Celebrex is the originator brand marketed by Pfizer. The product is approved in capsule strengths including 50 mg, 100 mg, 200 mg, and 400 mg in the United States, subject to market-specific labeling and availability (FDA, 2023).

Celecoxib is a small molecule, not a biologic. Biosimilar pathways do not apply. Generic applicants use the abbreviated new drug application, or ANDA, pathway and must demonstrate pharmaceutical equivalence and bioequivalence.

Item	Commercial assessment
Active ingredient	Celecoxib
Key strength	200 mg
Originator	Pfizer, Celebrex
Product class	Selective COX-2 inhibitor
Primary dosage form	Hard gelatin capsule
US regulatory pathway for generics	ANDA
Biosimilar exposure	None
Reference-product protection	Expired or commercially non-blocking in the United States
Main development risk	Dissolution and bioequivalence performance
Main commercial opportunity	Low-cost, reliable, differentiated oral delivery

The 200 mg strength is commercially important because it is used as a once-daily osteoarthritis regimen or as part of higher-dose regimens for selected indications. It also provides a practical platform for unit-dose packaging and lower-pill-burden products.

What excipients are used in the Celebrex 200 mg capsule?

The US Celebrex label identifies lactose monohydrate, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate as core inactive ingredients. The capsule shell contains gelatin and titanium dioxide, with printing inks used for product identification (FDA, 2023).

Functional role	Reference-product excipient	Formulation function
Diluent	Lactose monohydrate	Provides bulk and supports capsule fill weight
Wetting agent	Sodium lauryl sulfate	Improves wetting of hydrophobic celecoxib particles
Binder	Povidone	Supports granule or powder cohesion
Disintegrant	Croscarmellose sodium	Promotes capsule-fill dispersion after shell rupture
Lubricant	Magnesium stearate	Reduces adhesion during manufacturing
Capsule shell	Gelatin	Provides hard-shell oral dosage form
Opacifier	Titanium dioxide	Supports shell appearance and light protection
Identification	Printing ink	Product and strength identification

Celecoxib has poor aqueous solubility and is generally considered dissolution-limited at therapeutic concentrations. The formulation therefore needs reliable wetting, dispersion, and dissolution despite a relatively low active-ingredient dose-to-performance ratio. Sodium lauryl sulfate is particularly important in a conventional formulation because celecoxib is hydrophobic.

What excipient risks affect celecoxib 200 mg development?

The main risks are:

1. Dissolution sensitivity. Changes in particle size, polymorphic form, wetting-agent concentration, lubricant level, or blending time can change the dissolution profile.

2. Magnesium stearate over-lubrication. Excessive lubrication can create hydrophobic particle surfaces and slow dissolution.

3. Lactose compatibility. Lactose is widely used and cost-efficient, but it creates labeling considerations for patients with lactose intolerance and can create supply-chain complexity when manufacturers seek lactose-free positioning.

4. Sodium lauryl sulfate tolerability. The excipient is functional but may be unattractive in products positioned around gastrointestinal tolerability.

5. Shell variability. Gelatin introduces animal-origin, moisture, and temperature-control considerations. Hypromellose capsules can support vegetarian, halal, kosher, or non-animal positioning but require redevelopment of fill, shell moisture, and dissolution performance.

6. Powder flow and content uniformity. Low-dose active ingredient relative to total fill weight can make blend uniformity and segregation important process controls.

What excipient strategies can improve celecoxib 200 mg performance?

Conventional capsule optimization

The lowest-risk approach is to retain the hard capsule format and optimize the excipient system around dissolution and manufacturing efficiency. Candidate adjustments include:

• Replacing or reducing sodium lauryl sulfate with polysorbates, poloxamers, or other wetting systems.
• Comparing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or spray-dried co-processed fillers.
• Using crospovidone or sodium starch glycolate as alternatives to croscarmellose sodium.
• Replacing povidone with copovidone or hydroxypropyl cellulose where granulation or compactability requires adjustment.
• Optimizing magnesium stearate concentration and lubrication time.
• Evaluating low-moisture excipient grades for improved stability.

A conventional formulation has the highest probability of ANDA approval and the lowest development cost. Its commercial weakness is limited differentiation.

Lactose-free and patient-segmented capsules

A lactose-free 200 mg capsule can target patients who avoid lactose-containing medicines or pharmacies that prefer simplified inactive-ingredient profiles. The commercial opportunity is niche but practical, particularly if the product maintains reference-like dissolution without sodium lauryl sulfate.

A lactose-free product should not be marketed as clinically superior without supporting evidence. Its value is label differentiation, patient choice, and procurement flexibility.

Hypromellose capsules

Hypromellose shells can support non-animal and vegetarian positioning. They can also reduce dependence on gelatin supply and appeal to markets with religious or dietary restrictions.

The development challenge is that shell composition, moisture content, and rupture behavior can affect dissolution. A hypromellose product may require comparative dissolution across pH conditions and stability studies under elevated humidity.

Multiparticulate and sprinkle products

Celecoxib 200 mg can be developed as pellets, granules, or coated multiparticulates for patients with swallowing difficulty. A sprinkle capsule or sachet could create a stronger commercial position than a standard generic capsule.

The formulation must control:

• Taste and mouthfeel.
• Dose uniformity across multiparticulates.
• Coating robustness.
• Accidental chewing or crushing.
• Food-effect behavior.
• Stability after opening.
• Administration with soft food or liquid.

A sprinkle product may require a new drug application, a suitability petition, or another regulatory route rather than a simple ANDA, depending on the degree of dosage-form and labeling difference from the reference product.

Amorphous solid dispersions

Amorphous solid dispersion systems can increase apparent solubility and accelerate dissolution. Suitable carriers may include copovidone, povidone, hypromellose, hypromellose acetate succinate, or polyvinyl caprolactam-based polymers.

The main technical barrier is physical stability. Celecoxib may recrystallize during storage, especially under heat and humidity. Development requires solid-state characterization using differential scanning calorimetry, powder X-ray diffraction, thermogravimetric analysis, and accelerated stability testing.

An amorphous dispersion may support a differentiated product, but it also creates higher manufacturing, analytical, and regulatory costs. The strongest commercial case is a lower-dose or lower-volume dosage form, faster dissolution claim where permitted, or improved performance under fed and fasted conditions.

Nanocrystal and particle-engineering approaches

Nanocrystals can increase surface area and improve dissolution without large quantities of polymer. Wet milling, high-pressure homogenization, or precipitation methods can produce a nanosized celecoxib suspension or dried powder.

Commercial advantages may include:

• Faster dissolution.
• Lower reliance on surfactant loading.
• Potentially smaller dosage forms.
• Compatibility with capsules, tablets, or oral suspensions.

Risks include particle growth, aggregation, residual solvent or process impurities, scale-up complexity, and higher analytical burden. A nanocrystal product is more defensible from a formulation-IP perspective than a conventional generic, but its development costs are materially higher.

What formulation patents can protect a celecoxib 200 mg product?

Active-ingredient patent protection for celecoxib has expired in the United States. Commercial protection can still arise from later patents covering formulation architecture, particle size, solid-state form, manufacturing processes, dosage forms, or specific methods of use.

Protection category	Potential claim subject	Commercial value
Composition patent	Celecoxib with defined excipient ratios	Moderate if narrowly drafted
Solid-state patent	Polymorph, amorphous form, or co-crystal	Moderate to high if reproducible
Particle-size patent	Micronized or nanosized celecoxib	Moderate
Dispersion patent	Celecoxib-polymer solid dispersion	High if performance-linked
Capsule patent	Hypromellose, sprinkle, or modified shell system	Moderate
Manufacturing patent	Milling, granulation, drying, or coating process	Moderate
Method-of-use patent	Specific indication, population, or regimen	Variable and label-dependent
Packaging patent	Moisture-control or unit-dose system	Low to moderate

A formulation patent is strongest when it combines a narrowly defined composition with measurable performance, such as dissolution, stability, reduced food effect, or improved bioavailability. Broad claims covering routine excipient substitution are vulnerable to obviousness and written-description challenges.

What is the Orange Book and Paragraph IV status of celecoxib?

Celecoxib generic entry is governed by the reference listed drug, FDA exclusivity records, Orange Book listings, and any unexpired patent certifications applicable to a specific product. The original Celebrex exclusivity and core patent barriers have expired, allowing multiple generic manufacturers to enter the US market.

Paragraph IV certifications were commercially relevant during the historical patent-challenge period. Generic applicants used them to challenge patents as invalid, unenforceable, or not infringed. The current opportunity is primarily a post-exclusivity generic market rather than a first-to-file patent-challenge market.

An ANDA applicant still must assess:

• Current Orange Book patent listings.
• Patent expiration and pediatric exclusivity dates.
• Any later-listed formulation or method-of-use patents.
• Paragraph III versus Paragraph IV certification strategy.
• Label carve-outs for protected indications.
• 30-month stay exposure if a qualifying patent litigation event is triggered.

Because celecoxib is a mature product, the commercial advantage of a Paragraph IV filing is lower than it was for first-wave entrants. The value is higher for a differentiated formulation with independent patent claims.

What patent litigation and licensing issues affect celecoxib?

The major historical patent disputes concerned Pfizer’s Celebrex patents and generic challenges to the validity or scope of those rights. The core composition and use patents no longer create a broad US entry barrier.

Licensing opportunities are more likely to involve technology than the active ingredient. Potential deal structures include:

• Licensing a celecoxib nanocrystal platform.
• Acquiring a polymeric dispersion technology.
• Using a third-party capsule or multiparticulate manufacturing process.
• Licensing regional rights for a differentiated dosage form.
• Contract manufacturing with an excipient supplier that owns process know-how.

No biosimilar licensing strategy is relevant. A company seeking commercial differentiation should focus on formulation patents, manufacturing know-how, regulatory data, and supply agreements.

How strong is the patent estate for celecoxib 200 mg?

The patent estate is weak for an ordinary 200 mg immediate-release capsule containing conventional excipients. It can be materially stronger for a new delivery platform.

Product concept	Patent strength	Regulatory burden	Commercial positioning
Standard lactose capsule	Low	Low	Price and supply
Lactose-free capsule	Low to moderate	Low to moderate	Patient and procurement niche
Hypromellose capsule	Moderate	Moderate	Non-animal and regional access
Sprinkle formulation	Moderate to high	Moderate to high	Swallowing difficulty
Nanocrystal capsule	Moderate to high	High	Dissolution and size reduction
Amorphous dispersion	High if stable	High	Performance differentiation
Modified-release product	High	High	New dosing proposition

The strongest defensible strategy is a formulation with a clear technical effect and a manufacturing process that is difficult to reproduce without infringing or incurring high development costs.

What generic launch scenarios exist for celecoxib 200 mg?

Low-cost conventional generic

This scenario uses a standard hard gelatin capsule and reference-like excipients. It has the fastest route to market and the lowest unit cost. Competition is intense, and margins depend on manufacturing scale, supply reliability, and pharmacy-channel access.

Premium generic with excipient differentiation

A lactose-free or hypromellose capsule can command limited premium value in institutional, specialty-pharmacy, and international channels. The product needs a clear inactive-ingredient profile and reliable availability.

Specialty dosage form

A sprinkle, oral suspension, sachet, or fast-dissolving dosage form can target adherence and swallowing barriers. It may qualify for stronger formulation protection but requires a more complex regulatory strategy.

Technology-led product

A nanocrystal or amorphous-dispersion product can support formulation patents and possible licensing. This is the highest-risk strategy, but it offers the best opportunity to reduce direct price comparison with standard generics.

How does celecoxib compare with other NSAID products?

Celecoxib competes with generic ibuprofen, naproxen, diclofenac, meloxicam, etodolac, and other nonsteroidal anti-inflammatory drugs. Its commercial positioning is based on selective COX-2 inhibition, dosing convenience, and a different gastrointestinal risk profile from nonselective NSAIDs, while cardiovascular and other boxed-warning considerations remain important in labeling (FDA, 2023).

Excipient strategy can differentiate celecoxib more effectively than for highly commoditized ibuprofen because dissolution performance is more formulation-sensitive. The opportunity is strongest where a product can combine low pill burden with consistent exposure and a clearly defined patient-use advantage.

What are the geographic commercial opportunities?

The United States is a high-volume but price-competitive generic market. Europe and other regulated markets offer opportunities for lactose-free, non-animal, and differentiated capsule products, although local requirements for excipient labeling and bioequivalence apply.

Emerging markets may favor:

• Stable formulations that tolerate heat and humidity.
• Simple capsule-fill processes.
• Blister packaging with strong moisture protection.
• Lower-cost excipient systems.
• Reliable supply of gelatin, polymers, and surfactants.
• Local manufacturing or regional contract manufacturing.

A two-platform strategy is practical: a low-cost conventional capsule for tender markets and a differentiated non-animal, lactose-free, or multiparticulate product for higher-margin channels.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are not active-ingredient synthesis. They are powder handling, particle-size control, blend uniformity, dissolution reproducibility, shell compatibility, and stability.

Critical process parameters include:

• Celecoxib particle-size distribution.
• Mixing order and blending time.
• Wetting-agent dispersion.
• Granulation endpoint, if granulation is used.
• Lubrication time and magnesium stearate level.
• Capsule-fill weight variation.
• Environmental humidity.
• Packaging moisture transmission.

Manufacturing know-how can be commercially valuable even where patent protection is limited. A robust process that delivers consistent dissolution at scale can reduce batch failures and regulatory questions.

What revenue exposure and commercial upside are available?

Celecoxib is a mature generic market, so revenue depends more on volume, channel, and differentiation than on brand-like pricing. Standard capsules face rapid price erosion after multiple generic entrants. Higher-value opportunities include:

• Hospital and managed-care contracts requiring reliable supply.
• Private-label and regional generic partnerships.
• Specialty products for swallowing difficulty.
• Non-animal and lactose-free formulations.
• Licensing of enabling formulation technology.
• Combination products only where clinically and regulatorily justified.
• International markets with limited local competition.

A conventional 200 mg capsule is primarily a scale business. A protected delivery platform can become a licensing or specialty-generic business.

Key Takeaways

• Celecoxib 200 mg is a mature small-molecule product with expired core US exclusivity.
• The reference capsule uses lactose monohydrate, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate.
• Dissolution is the central formulation and bioequivalence risk because celecoxib is poorly water-soluble.
• A conventional generic offers the lowest regulatory risk but limited pricing power.
• Lactose-free, hypromellose, sprinkle, nanocrystal, and amorphous-dispersion products offer stronger differentiation.
• The strongest formulation patents link defined composition or process parameters to measurable dissolution, stability, or bioavailability effects.
• No biosimilar pathway applies.
• Manufacturing know-how, supply reliability, and excipient control are more important than core active-ingredient patent protection.
• The best commercial portfolio combines a low-cost standard capsule with one differentiated dosage form.

FAQs

Can celecoxib 200 mg be formulated without sodium lauryl sulfate?

Yes. Alternative wetting systems can be evaluated, including polysorbates, poloxamers, and polymeric dispersion approaches. The replacement must preserve dissolution and bioequivalence performance.

Is a lactose-free celecoxib 200 mg capsule commercially attractive?

Yes, but primarily as a niche differentiator. Its value is strongest in institutional procurement, specialty pharmacy, international markets, and patients seeking to avoid lactose-containing excipients.

Can celecoxib 200 mg be converted into a tablet?

Yes. A tablet can use direct compression, wet granulation, dry granulation, solid dispersion, or nanocrystal technology. The tablet is not automatically substitutable for the reference capsule and may require a distinct regulatory strategy.

Are celecoxib formulation patents stronger than active-ingredient patents?

For new products, they can be. A formulation patent is strongest when it protects a technically specific system with demonstrated dissolution, stability, or exposure advantages rather than a routine excipient substitution.

What is the most commercially practical innovation for celecoxib 200 mg?

A lactose-free, non-animal capsule with optimized wetting and dissolution is the lowest-risk differentiated option. A sprinkle or multiparticulate product offers greater commercial separation but carries higher regulatory and manufacturing complexity.

References

1. U.S. Food and Drug Administration. (2023). Celebrex (celecoxib) capsules: Prescribing information. Pfizer Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Department of Health and Human Services.

4. U.S. Patent and Trademark Office. (2024). Patent Center and patent term information. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.